Creo Medical Group
CREO · AIM · Health Care · mcap £46m · 10.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Results | Unaudited interim results
THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. |
−12.4% |
| 05 Aug 26 | Holding | Holding(s) in Company | |
| 28 Jul 26 | Trading update | H1-26 Trading Update
Continued commercial momentum and a materially lower cost base |
+0.0% |
| 23 Jul 26 | MicroBlate™ Flex exceeds 100 clinical cases
MicroBlate™ Flex exceeds 100 clinical cases as adoption builds |
−1.8% | |
| 06 Jul 26 | Award of Shares under Share Incentive Plan
Award of Shares under Share Incentive Plan and Director Dealings |
+0.0% | |
| 29 Jun 26 | Routine | Result of AGM | |
| 29 Jun 26 | AGM Statement
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, provides an update to shareholders ahead of its An |
+8.3% | |
| 23 Jun 26 | Appointment of Nominated Adviser /Corporate Broker
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the appointment of Shore Capital and Cor |
+0.0% | |
| 04 Jun 26 | Routine | Posting of 2025 Annual Report and Notice of AGM | |
| 28 May 26 | Holding | Holding(s) in Company | |
| 22 May 26 | Fundraise | Result of Placing
The Issue Price represents a premium of approximately 31.9 per cent. to the closing middle market price of 11.4 pence per Existing Ordinary Share on 21 May 2026, being the latest practicable date prior to the publication |
+27.5% |
| 22 May 26 | Fundraise | Proposed Placing to raise approximately £5.5m
Creo Medical Group plc (AIM:CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients (the "Company" or "Creo" and, together with its subs |
+27.5% |
| 22 May 26 | Results | FY25 Final Results
Strong financial and operational delivery, in-line with market expectations |
+27.5% |
| 22 May 26 | Proposed Sale of 49% Interest in Creo Medical SL
THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. |
+27.5% | |
| 07 May 26 | MicroBlate™ Fine commercial update
Creo Medical accelerates US clinical adoption and commercial rollout of MicroBlate Fine |
+5.2% | |
| 05 May 26 | SpydrBlade™ Flex used in novel BEAM procedures
Creo Medical's SpydrBlade™ Flex used in novel bariatric endoscopic technique |
+1.0% | |
| 30 Apr 26 | KOL presentations on Creo Core Products at DDW
KOL presentations on Creo Core Products at DDW |
+6.1% | |
| 29 Apr 26 | UK private hospital use Speedboat for cancer case
First UK private hospital use Speedboat for colorectal cancer case |
+1.0% | |
| 22 Apr 26 | Trading update | Positive Q1 trading update
Strong trading momentum continues with 60% year-on-year revenue growth in Q1 |
+3.9% |
| 16 Apr 26 | Disposal and outsourcing of manufacturing
Sale of manufacturing business to further reduce operating costs and improve margins |
+3.2% | |
| 24 Feb 26 | Appointment of Joint Corporate Broker
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the appointment of Shore Capital Stockbr |
+1.5% | |
| 20 Jan 26 | Trading update | FY25 Trading Update
A year of strong financial and operational delivery |
−5.1% |
| 14 Jan 26 | Award of Shares under Share Incentive Plan
Award of Shares under Share Incentive Plan and Director Dealings |
−2.3% | |
| 27 Oct 25 | Notice of Capital Markets Day
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that, further to the announcement on 7 O |
+1.1% | |
| 07 Oct 25 | Capital Markets Day update
CMD to be rearranged to allow clinician case using Creo products to be completed |
+0.0% |
Company filings. Not investment advice.